|

Poly-ICLC Clinical Trials

5 actively recruiting trials across 5 locations

Also known as: Hiltonol, Poly I:Poly C with Poly-L-Lysine Stabilizer, PolyI:PolyC with Poly-L-Lysine Stabilizer, Polyinosinic-Polycytidylic Acid Stabilized with Polylysine and Carboxymethylcellulose, Polyriboinosinic-Polyribocytidylic Acid-Polylysine Carboxymethylcellulose, Stabilized Polyriboinosinic/Polyribocytidylic Acid, poly-ICLC

Orange, California1 trial

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

UC Irvine Health/Chao Family Comprehensive Cancer Center

Phase 2

Boston, Massachusetts1 trial

Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM

Massachusetts General Hospital

Phase 1

St Louis, Missouri1 trial

Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease

Washington University School of Medicine

Phase 1

New York, New York1 trial

Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm

Icahn School of Medicine at Mount Sinai

Phase 1

Seattle, Washington1 trial

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

Fred Hutch/University of Washington Cancer Consortium

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.